» Articles » PMID: 18773878

DNA Damage and Homologous Recombination Signaling Induced by Thymidylate Deprivation

Overview
Date 2008 Sep 9
PMID 18773878
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (TS), but the types of damage and signaling responses remain incompletely understood. Thymidylate deprivation increases dUTP and uracil in DNA, which is removed by base excision repair (BER). Because BER requires a synthesis step, strand break intermediates presumably accumulate. Thymidylate deprivation also induces cell cycle arrest during replication. Homologous recombination (HR) is a means of repairing persistent BER intermediates and collapsed replication forks. There are also intimate links between HR and S-phase checkpoint pathways. In this study, the goals were to determine the involvement of HR-associated proteins and DNA damage signaling responses to thymidylate deprivation. When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (RTX), which specifically inhibits TS. To our knowledge, this is the first demonstration in mammalian cells that depletion of RAD51 causes sensitivity to thymidylate deprivation. Activation of DNA damage signaling responses was examined following treatment with RTX. Phosphorylation of replication protein A (RPA2 subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of RTX. Induction was much more striking following RTX treatment than with hydroxyurea, which is commonly used to inhibit replication. RTX treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied. Collectively, the results suggest that HR and S-phase checkpoint signaling processes are invoked by thymidylate deprivation and influence cellular resistance to thymidylate deprivation.

Citing Articles

Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.

Baxter M, Chapagai D, Craig S, Hurtado C, Varghese J, Nurmemmedov E ChemMedChem. 2020; 15(12):1058-1066.

PMID: 32232973 PMC: 7703809. DOI: 10.1002/cmdc.202000137.


Thiopurine-induced mitotic catastrophe in Rad51d-deficient mammalian cells.

Wyatt M, Reilly N, Patel S, Rajesh P, Schools G, Smiraldo P Environ Mol Mutagen. 2017; 59(1):38-48.

PMID: 28945288 PMC: 5771848. DOI: 10.1002/em.22138.


Homologous Recombination Repair Polymorphisms and the Risk for Osteosarcoma.

Goricar K, Kovac V, Jazbec J, Lamovec J, Dolzan V J Med Biochem. 2017; 34(2):200-206.

PMID: 28356832 PMC: 4922323. DOI: 10.2478/jomb-2014-0031.


Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage.

Yan Y, Han X, Qing Y, Condie A, Gorityala S, Yang S Oncotarget. 2016; 7(37):59299-59313.

PMID: 27517750 PMC: 5312313. DOI: 10.18632/oncotarget.11151.


Genomically Incorporated 5-Fluorouracil that Escapes UNG-Initiated Base Excision Repair Blocks DNA Replication and Activates Homologous Recombination.

Huehls A, Huntoon C, Joshi P, Baehr C, Wagner J, Wang X Mol Pharmacol. 2015; 89(1):53-62.

PMID: 26494862 PMC: 4702102. DOI: 10.1124/mol.115.100164.


References
1.
Thorslund T, West S . BRCA2: a universal recombinase regulator. Oncogene. 2007; 26(56):7720-30. DOI: 10.1038/sj.onc.1210870. View

2.
Ayusawa D, Koyama H, Shimizu K, Kaneda S, Takeishi K, Seno T . Induction, by thymidylate stress, of genetic recombination as evidenced by deletion of a transferred genetic marker in mouse FM3A cells. Mol Cell Biol. 1986; 6(10):3463-9. PMC: 367094. DOI: 10.1128/mcb.6.10.3463-3469.1986. View

3.
Li L, Berger S, Wyatt M . Involvement of base excision repair in response to therapy targeted at thymidylate synthase. Mol Cancer Ther. 2004; 3(6):747-53. View

4.
Liu J, Kuo S, Melendy T . Phosphorylation of replication protein A by S-phase checkpoint kinases. DNA Repair (Amst). 2006; 5(3):369-80. DOI: 10.1016/j.dnarep.2005.11.007. View

5.
Takemura Y, Jackman A . Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anticancer Drugs. 1997; 8(1):3-16. DOI: 10.1097/00001813-199701000-00001. View